Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. (NASDAQ: INMB) on November 25, 2019. The company is an emerging growth company incorporated in Nevada, focused on developing treatments for Alzheimer's disease. The report details corporate governance actions taken by the Board of Directors on the date of the report.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data provided relates to a specific equity compensation event:
- Options Issued: 1,785,000 options to purchase common stock.
- Exercise Price: $3.91 per share (based on the closing price on November 25, 2019).
- Recipients: Board members, officers, and consultants.
Material Changes
The primary material change reported is the approval and issuance of stock options to key personnel. The Board approved an aggregate of 1,785,000 options. Of these, 1,320,000 were granted to specific individuals listed in the filing, including the CEO, CFO, and CSO. The remaining options were issued to other consultants or board members not detailed in the specific grant table. All Board members abstained from voting on their respective grants.
Guidance, Outlook, and Other Events
Upcoming Events: The company announced a live webinar scheduled for December 3, 2019, at 1:00 p.m. EST. The event, titled "Bench to Bedside: A Pre-CTAD Webinar Highlighting an Alternative Approach for Alzheimer's Disease," is intended to highlight the company's approach to the disease prior to the CTAD conference.
Risks and Contingencies: The filing notes that the press release regarding the webinar is furnished as an exhibit and is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation into other filings.
Investor Verification Checklist
- Verify the total number of options outstanding post-grant to assess potential dilution.
- Confirm the vesting schedules for the 1,320,000 options granted to executives and directors (mostly 3-year pro rata monthly).
- Review the content of the upcoming December 3, 2019 webinar for updates on clinical progress or strategic shifts.
- Check subsequent filings for the full breakdown of the remaining 465,000 options (1,785,000 total minus 1,320,000 detailed) to identify other recipients.